GLAXOSMITHKLINE PLC Form 6-K November 07, 2008

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For period ending November 07, 2008

GlaxoSmithKline plc (Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS (Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Securities Exchange Act of 1934.

Yes No x

--

Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons

```
The a
dministrators of the GlaxoSmithKline Performance Share Plan
(the "Administrators")
notified the Company and
the under
-mentioned
person
s
on
7
November
2008
of
an
increase in
th
eir notional
interest
s
in
Ordinary
shares
at a price of £
11.66
per share
and
Ordinary
Share
ADRs at
a price of $
37.32
per ADR
following the notional re-investment of the dividend
to be
p
```

aid to shareholders on 8 January 2009

.

Ordinary shares	ADRs
5	
,	
625.13	
3,959.53	
352.25	1
	,
	835.07
28.07	41
000.00	.75
2,952.21	
1 111 87	
	738.09
	1,563.87
	,
	1015.50
452.42	
1,019.86	
340.46	
	shares 5 , 625.13 3,959.53 352.25 28.07 296.63 2,952.21 1,111.87 921.57 545.32 607.10 452.42 1,019.86

The Administrators also notified the Company on 7 November 2008

of a further increase in the notional interests of the undermentioned persons in

rdinary shares at a price of £11.67 following the notional re-investment of the dividend paid to shareholders on the

9 October 2008

.

Ordinary

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

shares

Mr A 690.66

Ρ

Witty

Mr A S Hussain 500.36

The notional dividends accrued will be paid out in proportion to the percentage of participants' Performance Share Plan holdings

that

V

est

following the end of the relevant three year measurement period.

This notification relates to

transaction

S

notified in accordance with

Disclosure

and Transparency

R

ule

S

3.1.4R(1)(a)

.

Victoria A Whyte Deputy Company Secretary

7

November

2008

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc

(Registrant)

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Date: 07 November 2008	
	By: VICTORIA WHYTE

Victoria Whyte Authorised Signatory for and on behalf of GlaxoSmithKline plc